Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0YODKD)
| ADC Name |
BIO-106
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BIO-106
Click to Show/Hide
|
|||||
| Organization |
Beckley Biopharma (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Anti-TROP2 antibody
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
TAMTM
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A non-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced/metastatic solid tumors with disease progression post-standard therapy, measurable disease (RECIST 1.1 or bone-only), and ECOG 0-1. Exclusions cover drug hypersensitivity, cardiac dysfunction, active infections (HIV/HBV/HCV/SARS-CoV-2), and untreated CNS metastases.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1) | ||||
| Primary Endpoint |
The Phase 1 escalation period assesses safety (AEs, SAEs, DLTs) over 1 year to determine MTD, while the Phase 2 expansion period evaluates anti-tumor activity through ORR, DCR, DOR, PFS, and OS over 2 years.
|
||||
| Other Endpoint |
Phase 1 measures anti-tumor activity (ORR, DCR, DOR, PFS, OS) over 1 year, while Phase 2 monitors AESIs and AEs/SAEs over 2 years. PK parameters (Cmax, AUC) and anti-drug antibodies for BIO-106 are tracked across both phases.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 study of BIO-106 as monotherapy or in combination with pembrolizumab in patients with advanced cancers (starbridge-1). | ||||
References